Phase II Trial of Pembrolizumab in Central Nervous System Metastases From Multiple Histologies
Latest Information Update: 15 Mar 2024
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Adenocarcinoma; Brain metastases; Breast cancer; Carcinoma; Malignant melanoma; Meningeal carcinomatosis; Neuroendocrine carcinoma; Neuroendocrine tumours; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pituitary cancer; Prostate cancer; Renal cell carcinoma; Sarcoma; Small cell lung cancer
- Focus Therapeutic Use
- 08 Mar 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2027.
- 08 Mar 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2026.
- 01 Jul 2023 Results published in the Nature Medicine